Literature DB >> 12697917

Urinalysis for interleukin-8 in the non-invasive diagnosis of acute and chronic inflammatory diseases.

A S Taha1, V Grant, R W Kelly.   

Abstract

BACKGROUND AND AIMS: Given its role in mediating inflammation, the use of urinary interleukin-8 (IL-8) was assessed in the non-invasive diagnosis of acute and chronic inflammatory diseases.
METHODS: IL-8 was measured by an enzyme linked immunosorbent assay in random urine samples (1 ml each) carrying code numbers and taken from 208 patients: 177 adults and 31 children presenting with a range of active or inactive inflammatory conditions.
RESULTS: In the appropriate controls and in patients with inactive inflammation, the median urinary IL-8 levels ranged from 7-12 pg/ml, compared with 104 pg/ml in active ulcerative colitis (p = 0.002), 54 in active Crohn's disease (p = 0.025), 93 in active rheumatoid arthritis (p = 0.001), 107 in acute cholecystitis (p<0.0001), 127 in acute appendicitis (p = 0.0001), and 548 pg/ml in urinary tract infection (p<0.0001). Children with non-viral inflammation/infection also had higher IL-8 values (median, 199 pg/ml; p = 0.0001) than those with viral infection (median, 7 pg/ml) or non-specific conditions (median, 10 pg/ml). In the study group as a whole urinary IL-8 values correlated positively with peripheral blood white cell count (r = 0.32; p < 0.001), erythrocyte sedimentation rate (r = 0.41; p<0.001), and C-reactive protein (r = 0.33; p<0.001).
CONCLUSION: Taking the appropriate clinical situation into account, urinary IL-8 measurement helps in the non-invasive assessment of active inflammation in at least a number of common acute and chronic conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697917      PMCID: PMC1742648          DOI: 10.1136/pmj.79.929.159

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  20 in total

1.  The renaissance of C reactive protein.

Authors:  M B Pepys; A Berger
Journal:  BMJ       Date:  2001-01-06

Review 2.  Chemokines, inflammation and the immune system.

Authors:  D D Taub; J J Oppenheim
Journal:  Ther Immunol       Date:  1994-08

3.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

4.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

5.  IL-8 in septic shock, endotoxemia, and after IL-1 administration.

Authors:  K J Van Zee; L E DeForge; E Fischer; M A Marano; J S Kenney; D G Remick; S F Lowry; L L Moldawer
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

6.  Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.

Authors:  R Daig; T Andus; E Aschenbrenner; W Falk; J Schölmerich; V Gross
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

7.  Altered urinary interleukin-8/creatinine ratio in peptic ulcer disease: pathological and diagnostic implications.

Authors:  A S Taha; R W Kelly; G Carr; B Stiemer; R Morton; R H Park; A D Beattie
Journal:  Am J Gastroenterol       Date:  1996-12       Impact factor: 10.864

8.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

9.  Interleukin 8: cells of origin in inflammatory bowel disease.

Authors:  M C Grimm; S K Elsbury; P Pavli; W F Doe
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

Review 10.  Ongoing advances in inflammatory bowel diseases, including maintenance therapies, biologic agents, and biology of disease.

Authors:  D R Mack
Journal:  Curr Opin Pediatr       Date:  1998-10       Impact factor: 2.856

View more
  6 in total

1.  Urine IL-8 concentrations in infectious and non-infectious urinary tract conditions.

Authors:  Maria Bitsori; Maria Karatzi; Helen Dimitriou; Eleni Christakou; Avrora Savvidou; Emmanouil Galanakis
Journal:  Pediatr Nephrol       Date:  2011-05-21       Impact factor: 3.714

2.  N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study.

Authors:  Luis G Guijarro; Jose Mate; Javier P Gisbert; Jose Luis Perez-Calle; Ignacio Marin-Jimenez; Encarna Arriaza; Tomas Olleros; Mario Delgado; Maria S Castillejo; David Prieto-Merino; Venancio Gonzalez Lara; Amado-Salvador Pena
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

3.  Discovery and validation of urine markers of acute pediatric appendicitis using high-accuracy mass spectrometry.

Authors:  Alex Kentsis; Yin Yin Lin; Kyle Kurek; Monica Calicchio; Yan Yan Wang; Flavio Monigatti; Fabien Campagne; Richard Lee; Bruce Horwitz; Hanno Steen; Richard Bachur
Journal:  Ann Emerg Med       Date:  2009-06-25       Impact factor: 5.721

4.  Hyperbilirubinemia as a predictor of gangrenous/perforated appendicitis: a prospective study.

Authors:  Poras Chaudhary; Ajay Kumar; Neeraj Saxena; Upendra C Biswal
Journal:  Ann Gastroenterol       Date:  2013

Review 5.  SARS-CoV-2: sewage surveillance as an early warning system and challenges in developing countries.

Authors:  Deepak Panchal; Om Prakash; Prakash Bobde; Sukdeb Pal
Journal:  Environ Sci Pollut Res Int       Date:  2021-03-17       Impact factor: 4.223

Review 6.  Future perspectives of wastewater-based epidemiology: Monitoring infectious disease spread and resistance to the community level.

Authors:  Natalie Sims; Barbara Kasprzyk-Hordern
Journal:  Environ Int       Date:  2020-04-04       Impact factor: 9.621

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.